Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. If you're a growth investor, you probably won't be interested in buying Pfizer stock. Pfizer's top-selling ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

PFE Factor-Based Stock Analysis May 28, 2025 — 09:40 am EDT Written by John Reese for Validea -> Below is Validea's guru fundamental report for PFIZER INC (PFE).

So far this year, Pfizer’s stock has declined 13.7% compared with a decrease of 3.6% for the industry. Pfizer Stock Performance Image Source: Zacks Investment Research ...

Pfizer 's (PFE -0.28%) management team is confident in its 2025 opportunities. *Stock prices used were the afternoon prices of May 20, 2025. The video was published on May 22, 2025.

Pfizer's built from many pieces that are moving in opposite directions. To make sure this stock isn't a yield trap destined to slash its dividend payout in the near term, let's weigh the good news ...

Looking ahead, Pfizer has maintained its 2025 sales forecast to be in the range of $61 billion to $64 billion, with adjusted earnings projected between $2.80 and $3.00 per share, compared to $63.6 ...

Pfizer Inc. (NYSE:PFE – Get Free Report) shares dropped 2.7% on Wednesday after UBS Group lowered their price target on the stock from $28.00 to $24.00. UBS Group currently has a neutral rating ...

The company’s stock value saw an initial plunge shortly after the tweet on July 9 — but a few hours later, they recovered. The drugmaker’s shares were up 0.3 percent at 2:17 p.m. that same day.